EDUCATION > Educational Programs > E-Learning > Videos/Webcasts > 2012 Annual Meeting Webcasts > Advanced Prostate Cancer > Module 4: Management of Prostate Cancer: A Case-Based Approach

Module 4: Management of Prostate Cancer: A Case-Based Approach

Activity Description

This activity will provide a practical, evidence-based approach for the management of everyday problems in the management of prostate cancer, using a case-based approach with examples from real practice. Topics will include developing appropriate screening strategies utilizing new information on the predictive value of PSA and new biomarkers (PCA3, and -2proPSA); how best to choose and follow patients on surveillance; long term data on outcomes after prostatectomy, external beam radiotherapy, and brachytherapy for low and intermediate risk disease; the emerging role of surgery as initial therapy for high risk disease; and an overview of the mechanism of action, potential benefits and appropriate use of newer agents for castrate-resistant disease.

Learning Objectives

After participating in this activity, participants should be able to:

  • design appropriate screening strategies based on individual demographics, risk factors, and PSA history and to incorporate new biomarkers into routine clinical practice
  • develop strategies for the appropriate use of transperineal saturation biopsy and endorectal MRI in the diagnosis and management of early stage prostate cancer
  • appraise the role of surveillance, focal therapy, surgery, and various forms of radiation therapy in patients with low and intermediate risk disease, including adjuavant and salvage radiation
  • enumerate and contrast the benefits and drawbacks of surgery vs. radiation-based approaches for the management of high risk localized disease
  • describe new therapeutic agents for the management of castrate resistant disease and outline a coherent strategy for their use


Eric A. Klein, MD, Course Director
Chair, Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, OH
Disclosures: Abbott Diagnostics: Scientific Study or Trial

Robert Dreicer, MD
Chair, Department of Solid Tumor Oncology
Cleveland Clinic
Cleveland, OH
Disclosures: Johnson and Johnson: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; EMD Serano: Scientific Study or Trial ; Millenium: Consultant or Advisor,Scientific Study or Trial

Andrew J. Stephenson, MD
Director, Center for Urologic Oncology
Glickman Urological & Kidney Institute
Cleveland Clinic
Cleveland, OH
Disclosures: Amgen: Consultant or Advisor,Meeting Participant or Lecturer ; Myriad Biosciences: Consultant or Advisor

Acknowledgement for Support

Support provided by educational grants from the following companies:

AMGEN Astellas Janseen
Medivation Millennium

Andriole et al, NEJM 362:1192, 2011

Attard, et al, J. Clin. Oncol. 2008

Bechis et al, JCO 29:235, 2011

Berglund et al, Urol 67:1253, 2006

Bill-Axelson, Holmberg, et al, NEJM 2005. Data from the Swedish randomized trial of prostatectomy vs. watchful waiting among men with localized prostate cancer

Caloglu et al, IJROBP 80:735, 2011

CAPSURE, Cancer 116:5226, 2010

Chun et al, Eur Urol 56:659, 2009

Ciezki et al, ASCO GU 2012

Cleveland Clinic, N = 267, 1998-2004

Clinical Trials, Accessed April 18, 2010. identifier: NCT00638690.

Danila DC, et al. J Clin Oncol. 2010;28:1496-1501; Reid AH, et al. J Clin Oncol. 2010;28:1489-1495.

de Bono J, et al. NEJM 364;1995 2011

de Bono JS et al. N Engl J Med. 2011;364(21):1995-2005

de la Taille et al, J Urol 185:2119, 2011

Eggener et al. J Urol 2011

Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001-3015.

Higano CS, et al. ASCO GU 2011. Abstract 134.

Hussain M, et al. J Clin Oncol 24:3984-3990

Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990.

Kantoff, P et al. N Engl J Med 363;5 2010

Klein et al, JAMA 306:1549, 2011

Klotz et al, JCO 28:126, 2010

Lawrentschuk and Fleshner, BJU Intl 103:730, 2009

Le et al, J Urol, 183:1355, 2010

Lee et al, J Urol 184:1958, 2010

Marberger et al, BJU Intl June 2011

Marshall et al, Cancer Prev Res 4:1761, 2011

Miocinovic et al, Urology 77:946, 2011

Montgomery BR, et al. Cancer Res 2008;68:4447-4454

Moussa AS, Jones JS. Urology 2010

Scher H, et al. 2012 Genitourinary Cancers Symposium

Scher H, et al. Urology 2000.

Scher HI, et al. Lancet. 2010;375:1437-1446

Scher HI, et al. Urology 2000 55:323-7.

Stephenson et al. ASCO 2009

Stephenson et al. J Clin Oncol 2007; Trock et al. Jama 2008

Theoret et al, NEJM 365:97, 2011

Thompson et al. J Urol 2009

Thompson et al. J Urol 2009; Bolla et al. Lancet 2005; Wiegel et al. J Clin Oncol 2009

Zelefsky et al, J Clin Oncol 28:1508; 2010


Term of Use